Subtopic Deep Dive
Endocannabinoid System Signaling
Research Guide
What is Endocannabinoid System Signaling?
Endocannabinoid system signaling encompasses the biosynthesis, release, uptake, degradation of endocannabinoids like anandamide (AEA) and 2-arachidonoylglycerol (2-AG), and their actions via CB1, CB2, and GPR55 receptors.
Key endocannabinoids signal through G-protein-coupled receptors primarily in the central nervous system (Zou and Kumar, 2018; 1281 citations). Regulatory enzymes include FAAH for AEA hydrolysis and MAGL for 2-AG degradation (Bisogno et al., 2001; 1278 citations). Over 10 highly cited papers from 2001-2018 detail receptor pharmacology and metabolic pathways.
Why It Matters
Endocannabinoid signaling modulates pain, appetite, and neuroinflammation, enabling cannabinoid therapeutics for schizophrenia (Leweke et al., 2012; 1024 citations) and Alzheimer's pathology via microglial blockade (Ramírez et al., 2005; 766 citations). GPR55 as a novel receptor expands drug targets (Ryberg et al., 2007; 1541 citations). CBD enhances AEA signaling by inhibiting uptake and hydrolysis (Bisogno et al., 2001; 1278 citations), supporting non-psychoactive treatments.
Key Research Challenges
GPR55 Receptor Validation
GPR55 activation by endocannabinoids remains debated beyond CB1/CB2 (Ryberg et al., 2007; 1541 citations). Functional assays show inconsistent coupling to G-proteins. Selective antagonists are lacking for signaling dissection.
Enzyme Inhibition Specificity
FAAH and MAGL inhibitors affect off-target TRP channels (De Petrocellis et al., 2010; 896 citations). CBD modulates VR1 and AEA hydrolysis non-selectively (Bisogno et al., 2001; 1278 citations). Balancing therapeutic efficacy requires precise enzyme profiling.
Dynamic EC Level Measurement
Endocannabinoid levels fluctuate with feeding and stress in hypothalamus (Kirkham et al., 2002; 778 citations). Fast feedback via glucocorticoid inhibition complicates assays (Di et al., 2003; 783 citations). Real-time quantification in vivo remains technically challenging.
Essential Papers
The diverse CB<sub>1</sub>and CB<sub>2</sub>receptor pharmacology of three plant cannabinoids: Δ<sup>9</sup>‐tetrahydrocannabinol, cannabidiol and Δ<sup>9</sup>‐tetrahydrocannabivarin
Roger G. Pertwee · 2007 · British Journal of Pharmacology · 1.9K citations
Cannabis sativa is the source of a unique set of compounds known collectively as plant cannabinoids or phytocannabinoids. This review focuses on the manner with which three of these compounds, (−)‐...
The orphan receptor GPR55 is a novel cannabinoid receptor
Erik Ryberg, Niklas Larsson, S. Sjögren et al. · 2007 · British Journal of Pharmacology · 1.5K citations
Background: The endocannabinoid system functions through two well characterized receptor systems, the CB 1 and CB 2 receptors. Work by a number of groups in recent years has provided evidence that ...
Cannabis sativa: The Plant of the Thousand and One Molecules
Christelle M. André, Jean-François Hausman, Gea Guerriero · 2016 · Frontiers in Plant Science · 1.5K citations
Cannabis sativa L. is an important herbaceous species originating from Central Asia, which has been used in folk medicine and as a source of textile fiber since the dawn of times. This fast-growing...
Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System
Shenglong Zou, Ujendra Kumar · 2018 · International Journal of Molecular Sciences · 1.3K citations
The biological effects of cannabinoids, the major constituents of the ancient medicinal plant Cannabis sativa (marijuana) are mediated by two members of the G-protein coupled receptor family, canna...
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide
Tiziana Bisogno, L Hanŭs, Luciano De Petrocellis et al. · 2001 · British Journal of Pharmacology · 1.3K citations
(−)‐Cannabidiol (CBD) is a non‐psychotropic component of Cannabis with possible therapeutic use as an anti‐inflammatory drug. Little is known on the possible molecular targets of this compound. We ...
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
F. Markus Leweke, Daniele Piomelli, Franziska Pahlisch et al. · 2012 · Translational Psychiatry · 1.0K citations
Cannabidiol is a component of marijuana that does not activate cannabinoid receptors, but moderately inhibits the degradation of the endocannabinoid anandamide. We previously reported that an eleva...
Effects of cannabinoids and cannabinoid‐enriched <i>Cannabis</i> extracts on TRP channels and endocannabinoid metabolic enzymes
Luciano De Petrocellis, Alessia Ligresti, Aniello Schiano Moriello et al. · 2010 · British Journal of Pharmacology · 896 citations
BACKGROUND AND PURPOSE Cannabidiol (CBD) and Δ 9 ‐tetrahydrocannabinol (THC) interact with transient receptor potential (TRP) channels and enzymes of the endocannabinoid system. EXPERIMENTAL APPROA...
Reading Guide
Foundational Papers
Start with Pertwee (2007; 1851 citations) for CB1/CB2 basics, Ryberg et al. (2007; 1541 citations) for GPR55 discovery, and Bisogno et al. (2001; 1278 citations) for CBD-endocannabinoid interactions to build core signaling knowledge.
Recent Advances
Zou and Kumar (2018; 1281 citations) reviews CNS functions; Leweke et al. (2012; 1024 citations) shows clinical AEA enhancement in schizophrenia.
Core Methods
Receptor binding (Pertwee 2007), metabolic enzyme assays (Bisogno 2001), TRP channel electrophysiology (De Petrocellis 2010), hypothalamic slice recordings (Di 2003).
How PapersFlow Helps You Research Endocannabinoid System Signaling
Discover & Search
Research Agent uses searchPapers and citationGraph on 'endocannabinoid signaling CB1 CB2 GPR55' to map 10+ high-citation papers like Ryberg et al. (2007; 1541 citations), then exaSearch for FAAH/MAGL regulators and findSimilarPapers for Zou and Kumar (2018).
Analyze & Verify
Analysis Agent applies readPaperContent to Pertwee (2007) for CB1/CB2 pharmacology details, verifyResponse (CoVe) to cross-check GPR55 claims against Ryberg et al. (2007), and runPythonAnalysis for statistical verification of citation networks or EC level data from Kirkham et al. (2002) using pandas plots; GRADE grading scores evidence strength for therapeutic claims.
Synthesize & Write
Synthesis Agent detects gaps in GPR55 signaling via contradiction flagging across Ryberg (2007) and Zou (2018), while Writing Agent uses latexEditText, latexSyncCitations for Pertwee (2007), and latexCompile to generate review sections; exportMermaid diagrams receptor-enzyme pathways.
Use Cases
"Plot endocannabinoid levels from feeding studies in Kirkham 2002 and similar papers"
Research Agent → searchPapers('2-AG hypothalamus feeding') → Analysis Agent → readPaperContent(Kirkham et al., 2002) → runPythonAnalysis(pandas data extraction, matplotlib EC level plots) → researcher gets quantified graphs of 2-AG changes.
"Write LaTeX review on CBD effects on FAAH and AEA signaling"
Research Agent → citationGraph(Bisogno et al., 2001) → Synthesis Agent → gap detection → Writing Agent → latexEditText(draft), latexSyncCitations(Leweke 2012), latexCompile → researcher gets compiled PDF with figures.
"Find code for simulating CB1 receptor signaling dynamics"
Research Agent → paperExtractUrls(Zou and Kumar 2018) → Code Discovery → paperFindGithubRepo → githubRepoInspect → researcher gets runnable Python models of G-protein coupling.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers on 'endocannabinoid signaling enzymes', structures report with GRADE-scored sections on FAAH/MAGL (Bisogno 2001). DeepScan applies 7-step CoVe to validate GPR55 novelty (Ryberg 2007) with checkpoints. Theorizer generates hypotheses on CBD-TRP interactions from De Petrocellis (2010).
Frequently Asked Questions
What defines endocannabinoid system signaling?
It covers biosynthesis/release of AEA/2-AG, signaling via CB1/CB2/GPR55, and degradation by FAAH/MAGL (Zou and Kumar, 2018).
What are key methods in this subtopic?
Radioligand binding for receptor pharmacology (Pertwee, 2007), enzymatic assays for FAAH inhibition (Bisogno et al., 2001), and LC-MS for EC quantification (Kirkham et al., 2002).
What are seminal papers?
Pertwee (2007; 1851 citations) on CB1/CB2 pharmacology; Ryberg et al. (2007; 1541 citations) identifying GPR55; Bisogno et al. (2001; 1278 citations) on CBD-FAAH targets.
What open problems exist?
GPR55 physiological roles, selective enzyme inhibitors avoiding TRP off-targets (De Petrocellis et al., 2010), and in vivo EC dynamics during stress (Di et al., 2003).
Research Cannabis and Cannabinoid Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Endocannabinoid System Signaling with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Cannabis and Cannabinoid Research Research Guide